Boardroom Alpha
Boardroom Alpha
VCEL · Current Report (Form 8-K) · Filed May 18, 2026

Vericel Corp — Current Report (Form 8-K)

Form
8-K
Filed
May 18, 2026
Period
May 18, 2026
Ticker
VCEL
Accession
0001140361-26-021892
Boardroom Alpha · Filing insights

Vericel amended its bylaws to reflect a new principal executive office address in Burlington, MA, effective May 18, 2026.

About Vericel Corp
Market cap
$1.8B
1Y TSR
−18.8%
3Y TSR
−0.3%
Board grade
B
Sector
Healthcare
CEO
Dominick Colangelo
Last annual meeting: Apr 29, 2026 · View full Vericel Corp profile →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of Earliest Event Reported):  May 18, 2026

Vericel Corporation
(Exact name of registrant as specified in its charter)
 
Michigan
001-35280
94-3096597
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

25 Blue Sky Drive


Burlington, MA

01803
(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code:  (617) 588-5555

64 Sidney Street
Cambridge, MA 02139
 Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class

Trading Symbol(s)

Name of each exchange on which registered
Common Stock, no par value

VCEL

NASDAQ
 
Indicate by a check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§240.12b-2 of this chapter). Emerging Growth Company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.03
Amendments to Articles of Incorporation or Bylaws.

Effective May 18, 2026, the Board of Directors of Vericel Corporation, a Michigan corporation (the “Company”), approved an amendment to the Company’s bylaws. The amendment accounts for the change in the address of the Company’s principal executive offices as a result of its move to a new global headquarters, located at 25 Blue Sky Drive, Burlington, Massachusetts 01803.  This description is qualified in its entirety by reference to the text of the Second Amended and Restated Bylaws of Vericel Corporation filed as Exhibit 3.1 to this Report, which is incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits
 
(d) Exhibits.
 
Exhibit No.
 
Description
3.1
 
104  
Cover Page Interactive Data File (embedded within the Inline XBRL)


EXHIBIT INDEX

Exhibit No.
 
Description
3.1
 
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Vericel Corporation
     
Date:  May 18, 2026
By:
/s/ Sean C. Flynn
   
Name: Sean C. Flynn
   
Title:  Chief Legal Officer

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Vericel Corp (VCEL)

Reference

Frequently asked questions

When did Vericel Corp file this 8-K?
Vericel Corp (VCEL) filed this Current Report (Form 8-K) with the SEC on May 18, 2026. The accession number assigned by EDGAR is 0001140361-26-021892.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Vericel amended its bylaws to reflect a new principal executive office address in Burlington, MA, effective May 18, 2026. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Vericel Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Vericel Corp has filed under CIK 887359, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer